Dr. Lee-Ling Lim is Professor of Medicine, UM and Head of the Diabetes Care Unit, Universiti Malaya Medical Centre. As a clinician-scientist, her major areas of interest include cardiometabolic medicine and intergenerational diabetes with translational and implementation science components.  Dr. Lim sits on the Working Groups of The Lancet Commission on Diabetes and the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) Precision Medicine in Diabetes Initiative, who provide authoritative resources in tackling the global diabetes epidemic. She recognizes that every person with diabetes and non-communicable disease (NCD) is unique and warrants personalized care. To revolutionize health care, Dr. Lim aims to advance the implementation of Precision Medicine in Diabetes and NCD, taking into account differences in clinical presentation, genes, and lifestyles in Malaysian populations. These have led to several collaborations with the USA, UK, and other Asian countries. She has published in numerous high-impact journals including The Lancet, Nature, Diabetes Care, and Science Bulletin.  Dr. Lim has received several awards including the World’s Top 2% Scientists by Stanford University for 3 consecutive years (2022-2024), the EFSD Albert Renold Fellowship, the USA Endocrine Society Outstanding Abstract Award, and a scholarship funded by the USA NIH National Institute of General Medical Sciences for training in statistical genetics at the University of Washington, USA. She is an Editorial Board Member of several Tier 1 Web of Science-indexed journals (BMC Medicine, Diabetes/Metabolism Research & Reviews, and Diabetes & Metabolism). Dr. Lim is an article reviewer for 29 leading academic journals including the European Heart Journal, Annals of Internal Medicine, Diabetes Care, PLoS Medicine, and European Journal of Preventive Cardiology.

Syazreen Nadia, a Ph.D. graduate in Organic Chemistry from Universiti Malaya, brings expertise in natural products, bioorganic chemistry, molecular docking, and formulation products. With extensive research in bioactive compounds and enzyme inhibition, she has contributed significantly to scientific advancements. Her professional experience in academia and industry, including roles in R&D, quality control, and sales, making her a well-rounded expert in chemistry and product development.

  Professor Hany Ariffin  is  Professor of Paediatrics and Head of the Division of Paediatric Haematology-Oncology and Blood & Marrow Transplantation at the University of Malaya Medical Centre (UMMC). She also heads the Biobank Unit in the Faculty of Medicine, UM.  Her main research interest is childhood leukaemia and she has been the Malaysian lead for the Malaysia-Singapore (MASPORE) Leukaemia Study Group since 2003. Her other research areas include childhood cancer survivorship, stem cell transplantation and inherited cancers, particularly related to mutations in the tumour suppressor gene, TP53. In 2015, she won the Anugerah Akademik Negara award and in 2018 received the Distinguished Researcher Award from University Malaya. Professor Hany is chairperson of the paediatric oncology accreditation committee for the National Specialist Register and a past president of the Malaysian Society of Paediatric Haematology-Oncology. She is also the chairperson of the VIVA-Asia Bone Marrow Transplantation Consortium for 2023/2024.  As co-chair of the Asian Childhood Cancer Alliance, Professor Hany works with regional colleagues as well as StJude Children's Research Hospital  to support the WHO Global Initiative for Childhood Cancer (WHO-GICC). The project's tagline is: “60 by 30” - which refers to the aim of reaching at least a 60% survival rate for children with cancer by 2030, thereby saving an additional one million lives around the world.  Professor Hany has been a reviewer for many scientific journals and is currently an Associate Editor (Tumour Biology) for Technology in Cancer Reseach &Treatment.